Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Advisors Lukewarm On Lower Extremity PAD Intervention Evidence

This article was originally published in The Gray Sheet

Executive Summary

The Medicare Evidence Development and Coverage Advisory Committee voted low to moderate support for the scientific evidence backing endovascular and other interventions to treat lower extremity peripheral artery disease.

You may also be interested in...



Let The U.S. Drug-Coated Balloon Battle Begin

Medtronic gained FDA approval for its drug-coated balloon for the peripheral artery, as expected, and it is now gunning to take share from first-to-market C.R. Bard with the help of impressive clinical data and a formidable Covidien peripheral vascular device sales force.

Peripheral Artery Disease: Treatments And Diagnostics Poised For Growth

The market for peripheral vascular interventions and diagnostics is poised for significant growth in the years ahead, driven by an aging population and the growing incidence of peripheral vascular disease, along with new technological developments such as drug-eluting balloons, which are inching closer to regulatory approval in the US.

Eli Lilly To Explore MiNA's Small Activating RNA Technology

Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.

Topics

Related Companies

UsernamePublicRestriction

Register

MT034080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel